Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

Aim To evaluate the effect of alirocumab on frequency of standard apheresis treatments [weekly or every 2 weeks (Q2W)] in heterozygous familial hypercholesterolaemia (HeFH). Methods and results ODYSSEY ESCAPE (NCT02326220) was a double-blind study in 62 HeFH patients undergoing regular weekly or Q2W...

Descripción completa

Detalles Bibliográficos
Autores principales: Moriarty, Patrick M., Parhofer, Klaus G., Babirak, Stephan P., Cornier, Marc-Andre, Duell, P. Barton, Hohenstein, Bernd, Leebmann, Josef, Ramlow, Wolfgang, Schettler, Volker, Simha, Vinaya, Steinhagen-Thiessen, Elisabeth, Thompson, Paul D., Vogt, Anja, von Stritzky, Berndt, Du, Yunling, Manvelian, Garen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Fasttrack Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5233802/
https://www.ncbi.nlm.nih.gov/pubmed/27572070
http://dx.doi.org/10.1093/eurheartj/ehw388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5233802/
https://www.ncbi.nlm.nih.gov/pubmed/27572070
http://dx.doi.org/10.1093/eurheartj/ehw388

Ejemplares similares